Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALDX
Nasdaq
8731
https://www.aldeyra.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aldeyra Therapeutics Inc
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
- Feb 7th, 2023 12:00 pm
Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit
- Jan 12th, 2023 11:37 am
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
- Dec 21st, 2022 12:00 pm
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
- Dec 13th, 2022 6:37 pm
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
- Dec 13th, 2022 1:00 pm
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
- Dec 1st, 2022 1:00 pm
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
- Nov 29th, 2022 1:00 pm
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
- Nov 10th, 2022 12:00 pm
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
- Nov 3rd, 2022 12:00 pm
Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position
- Nov 2nd, 2022 5:45 pm
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
- Oct 26th, 2022 12:00 pm
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
- Oct 6th, 2022 4:23 pm
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
- Oct 6th, 2022 11:00 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
- Oct 5th, 2022 8:05 pm
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
- Sep 14th, 2022 12:00 pm
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
- Sep 7th, 2022 12:00 pm
Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
- Sep 1st, 2022 10:56 am
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
- Aug 15th, 2022 1:55 pm
Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript
- Aug 7th, 2022 7:00 am
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
- Aug 5th, 2022 11:00 am
Scroll